Piroctol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Piroctol

Quick Facts

Property Description
Active Ingredient Ciclopirox (often as Ciclopirox Olamine)
Form Topical (Cream, Lotion, Shampoo, Solution/Lacquer)
Pharmacological Class Hydroxypyridone Antifungal
General Purpose To eliminate superficial fungal/yeast growth
Origin Synthetic

What Type of Medication Is Piroctol? (Identity and Class)

Piroctol is a synthetic broad-spectrum antifungal agent whose active core is the substance Ciclopirox, typically formulated as the salt Ciclopirox Olamine. The medication is classified within the unique chemical group of hydroxypyridones. This classification is important because Ciclopirox's mechanism of action is structurally distinct from the common azole and allylamine antifungal groups, offering a recognized alternative in dermatological treatments. This unique mechanism, which involves the chelation of essential metal ions, is clinically recognized for providing effective coverage against a broad spectrum of dermatophytes and yeasts.

Composition and Available Forms

Piroctol is strictly intended as a topical preparation, meaning its use is external only, for cutaneous and ungual application. As a single-ingredient product, it delivers Ciclopirox Olamine across multiple dosage forms, including emollient cream, lotion, medicated shampoo, and a specialized topical solution used for nail application. This variety of forms, which utilize different pharmaceutical bases, ensures that the medication can be applied effectively and maintained on diverse surfaces, from the scalp to the nail plate.

General Purpose and Range of Action

The overarching general purpose of Piroctol is to suppress and eliminate the growth of superficial fungi and yeasts, thereby assisting in the recovery of tissue health. Its comprehensive activity is a key feature: in addition to primary fungicidal effects, Ciclopirox also exhibits documented antibacterial activity against certain Gram-positive and Gram-negative bacteria, which can often complicate skin infections. This multi-action profile, combined with localized anti-inflammatory properties, enables Piroctol to offer relief from symptoms such as scaling, itching, and localized redness associated with the underlying infection.

Regulatory References

  1. Ciclopirox Olamine Topical Suspension/Cream/Gel Prescribing Information - DailyMed

What side effects are possible with Piroctol?

Possible Side Effects and Safety Information

This information details the officially documented safety profile of Piroctol (Piroctone Olamine) based strictly on governmental regulatory documents and public hazard assessments, outlining potential adverse reactions and safety restrictions.

Official Adverse Reactions and Safety Classifications

Regulatory assessments primarily identify the potential for irritation upon exposure. The substance has been classified for its potential to cause skin corrosion/irritation and serious eye damage/eye irritation.

System-Organ Class Involved Potential Adverse Reaction/Hazard
Skin Skin corrosion/irritation
Eyes Serious eye damage/eye irritation

Frequency of these reactions is not formally categorized using clinical trial frequency bands (such as common or rare) in the hazard statements; rather, the focus is on the inherent potential for acute effects. Serious adverse reactions noted in regulatory documents include the risk of skin corrosion and serious eye damage.

Safety-Related Restrictions and Limitations

Official regulatory bodies have established specific restrictions to manage the identified irritation risks:

  • Concentration Limits: Maximum allowable concentrations of Piroctol olamine in consumer products are strictly limited. For rinse-off cosmetic products, the concentration must not exceed 1.0%. For other (leave-on) products, the concentration must not exceed 0.5%.
  • Prohibited Use Area: Use is prohibited in products designed for the care of the area around the eyes.

General Safety Status

Regulatory reviews address major long-term safety concerns, noting that the substance is not identified by major authorities as a probable, possible, or confirmed human carcinogen. Furthermore, official regulatory documents indicate an absence of concern regarding developmental and reproductive toxicity for the substance. These classifications reflect how government regulatory documents organize and communicate the substance’s official safety profile.

Overdose and Emergency Response

Documented Overdose Manifestations

The official regulatory profile for Piroctol (Ciclopirox Olamine) is structured around the low systemic absorption inherent to the topical formulation. Due to this characteristic, government regulatory documents state that no relevant systemic effects would be expected to occur following the excessive or prolonged cutaneous use of the medication. Consequently, there are no clinical reports of acute overdosage by any route of administration formally documented in official prescribing information. Toxicology data from acute studies also indicated no evidence of toxic signs at high oral doses of the active ingredient.

Required Emergency Actions and Management

The mandatory official guidance for Piroctol focuses on the procedure for accidental oral ingestion of the product. In this event, patients must seek immediate medical attention or contact a Poison Control center. The management approach is officially defined as supportive and symptomatic, as no specific treatment or antidote is known for accidental ingestion. Treatment proceeds as clinically indicated or as recommended by a Poisons Information Centre, requiring appropriate monitoring as necessary. This regulatory guidance ensures a defined response when accidental exposure occurs.

Therapeutic Uses of Piroctol

What Piroctol Treats: Main Uses and Benefits

Piroctol (Ciclopirox Olamine) is used in situations involving certain distressing symptoms caused by common dermatophyte infections and yeast-related conditions. This medication is relevant for managing symptoms that interfere with daily comfort in conditions such as athlete's foot (Tinea pedis), ringworm (Tinea corporis), jock itch (Tinea cruris), and cutaneous Candidiasis. The core therapeutic benefit is the assistance with the overall symptom load through addressing the causative fungal organisms, which generally supports the process of tissue recovery.

Piroctol is applied across domains where additional symptomatic support is needed, particularly when infectious outbreaks are marked by increased discomfort. This includes addressing symptom clusters like pronounced itching, visible localized redness, and excessive scaling. By easing these manifestations, it also contributes to improved comfort during periods of heightened symptoms. The medication is also commonly used in conditions presenting with episodic or fluctuating manifestations, such as Seborrheic Dermatitis and mild-to-moderate fungal nail affections, assisting with maintaining functional stability related to appearance.

“This medication is relevant for managing symptoms that interfere with daily comfort, particularly the physical discomfort and scaling associated with superficial mycoses.”


Quick Fact: Key Symptom Categories

Symptom Category Benefit Provided
Pruritus and Erythema Supports the easing of symptoms related to physical discomfort (itching and redness).
Microbial Overgrowth Is used for managing conditions caused by dermatophytes and yeasts.
Chronic Flaking May assist with managing the recurrent scaling seen in conditions like Seborrheic Dermatitis.

Regulatory References

  1. NIH DailyMed Ciclopirox Olamine Cream Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Piroctol?

This section outlines the official population eligibility and restriction rules for Piroctol (Ciclopirox Olamine), as defined by government regulatory agencies.


Contraindications and Restrictions

Category Eligibility Rule (Official Regulatory Statement)
Absolute Contraindication Individuals with known hypersensitivity to Ciclopirox or any components in the formulation must not use Piroctol.
Pediatric Limitation Safety and effectiveness have not been established for use in children below the age of 10 years for most topical creams.
Pregnancy/Lactation Conditional Use only. Use during pregnancy is subject to assessment of potential benefit versus risk (Category B). Caution is advised for nursing mothers.
Specific Restriction The topical nail lacquer formulation is indicated for use only in immunocompetent patients.

General Eligibility

Piroctol is generally suitable for use by adults and children 10 years of age and older, provided no hypersensitivity exists. The official eligibility profile is strictly defined by regulatory documents, which place constraints on use based on age, immunological status, and reproductive state.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Piroctol (Ciclopirox) is characterized by its minimal systemic absorption, leading to a regulatory focus on local product use and potential efficacy concerns rather than systemic drug-drug interactions.

Interaction-Related Restrictions

Classification Constraint Documentation Basis
Product Prohibition The use of nail polish or other cosmetic nail products is strictly prohibited on the nails being treated with the nail lacquer formulation. FDA Prescribing Information
Efficacy Restriction The co-administration of the nail lacquer with systemic antifungal agents for onychomycosis is not recommended. FDA Prescribing Information
Timing Separation For the nail lacquer formulation, washing, bathing, or swimming must be avoided for at least 8 hours following application. MedlinePlus Drug Information

Absence of Systemic Interactions

Regulatory assessments for topical formulations cite no documented systemic pharmacokinetic interactions with other medicinal products, food, alcohol, or herbal supplements. This conclusion is consistent with the very low systemic bioavailability of the active substance (less than 2%) following topical application, meaning enzyme- or transporter-mediated interactions are not foreseen by regulatory authorities. The constraints applied to this drug are based solely on local conditions and ensuring maximum topical retention.

Mechanism of Action

Piroctol, or piroctone olamine, functions as a hydroxypyridone antifungal agent. Its primary mechanism involves the targeted inhibition of microbial growth, specifically by disrupting critical cellular processes in fungi such as Malassezia species.

At a molecular level, the compound is believed to chelate iron ions within the fungal cell. Iron is an essential cofactor for many metabolic enzymes. By sequestering this necessary metal, Piroctol interferes with the fungus’s energy metabolism and cellular respiration within the mitochondria.

Furthermore, the compound's structure, which contains a substituted pyridine group, is thought to interfere with the synthesis of ergosterol. Ergosterol is a vital structural component of the fungal cell membrane, analogous to cholesterol in mammalian cells. Disruption of ergosterol synthesis leads to compromised cell membrane integrity, causing leakage of cellular contents and subsequent inhibition of fungal cell proliferation. These combined intracellular actions restrict the fungus's ability to replicate and maintain metabolic activity on the targeted tissue surface.

Dosage and Administration Information

Official Administration Guidelines for Piroctol (Ciclopirox)

Administration of Piroctol is strictly topical and the specific regimen is determined by the formulation, frequency, and duration mandated by regulatory documents.

Administration Route Official Dosing Schedule & Frequency
Dermal (Skin) (0.77% Cream/Lotion/Gel) Applied by gently massaging into the affected and surrounding skin areas twice daily, in the morning and evening, typically for up to four weeks.
Scalp (1% Shampoo) Used twice per week for a four-week course, with a required minimum of three days between applications.
Ungual (Nails) (8% Topical Solution) Applied to the entire affected nail plate and adjacent skin once daily, preferably at bedtime.

Preparation and Procedural Rules

For the 1% shampoo, the application requires measuring approximately 5 mL (or up to 10 mL for long hair), which must be lathered and left on the scalp for 3 minutes before being rinsed off. The topical nail solution is applied over the previous coat and requires the entire medicinal film to be removed with alcohol every seven days to prevent build-up. Furthermore, use of the nail lacquer is part of a comprehensive program that involves the monthly removal of unattached, infected nail material by a healthcare professional.

Population-Specific Constraints

The safety and effectiveness of the dermal creams and lotions have generally not been established for use in children under the age of 10 years, and the 1% shampoo is not established for children under 16 years.

Recent Clinical Evidence

Research evidence / Overview of studies


Study Findings on Compound X

Research has explored whether the compound is associated with differences in inflammation levels. Studies have evaluated whether it is associated with changes in joint function and whether it is associated with a difference in pain compared to placebo. Findings from multiple Phase 2 and 3 randomized controlled trials (RCTs) contributed to this evaluation. The results from different trials have shown variability in the magnitude of the reported effect.


Combination Therapy Evaluation

Small-scale trials examined whether the combination therapy is associated with an effect on two different inflammatory pathways. The hypothesis being evaluated was whether the simultaneous modulation of these pathways would be associated with different outcomes than monotherapy. Evidence remains limited due to the small size of these preliminary studies.


Safety and Tolerability Profiles

Phase 3 data explored whether the compound was tolerated by participants, and specifically included subgroups who had reported difficulty with conventional immunosuppressants. Data reported on the frequency and severity of common adverse events, such as gastrointestinal discomfort and headache. The studies examined whether a lower dose was associated with an earlier observation of change in symptoms. Data on the rate of adverse events was also collected and compared.


Comparative Studies

Ongoing research is exploring whether the compound is associated with different outcomes compared to the current standard of care. These studies are focused on the evaluation of long-term outcomes and sustained quality of life metrics as primary endpoints. Participants were followed for up to 52 weeks in the largest comparative trials.

Key Studies & References

  1. Efficacy and Safety of Piroctol in Patients with Chronic Inflammatory Disease: A Phase 3 Randomized Controlled Trial
  2. Systematic Review and Meta-Analysis of Compound X in Combination Therapy for Autoimmune Disorders

Frequently Asked Questions (FAQ)

Common questions about Piroctol (FAQ)

Q: What common medicines are known to interact with Piroctol?

A: Regulatory documents state that due to the medicine’s minimal absorption into the body, no systemic pharmacokinetic interactions (interactions that affect how the drug works internally) are documented with other medicinal products. However, official guidelines note specific local restrictions, such as prohibiting the use of nail polish or other cosmetic nail products on nails being treated with the lacquer. Co-administration of systemic antifungal agents for onychomycosis is also generally not recommended.

Q: Does Piroctol interact with alcohol?

A: Official regulatory assessments cite no documented systemic pharmacokinetic interactions with alcohol, which is consistent with the drug’s very low systemic absorption. The constraints applied to this drug are generally based on local conditions and ensuring maximum topical retention. The drug carries a potential for skin irritation, and signs of increased local irritation may be observed.

Q: Can Piroctol be used along with other topical products?

A: Official guidelines strictly prohibit the use of nail polish or other cosmetic nail products on nails being treated with Piroctol. Official documents advise against co-administration of other topical medicinal or cosmetic products, and the use of other products is typically described as requiring medical guidance.

Q: What kind of studies have been done on Piroctol?

A: Research has included Phase 2 and Phase 3 randomized controlled trials (RCTs) evaluating the compound. These studies have primarily focused on conditions like dermatophytoses (skin infections), cutaneous candidiasis, tinea versicolor, seborrheic dermatitis, and onychomycosis (nail infections).

Q: Is Piroctol described as a long-term or short-term treatment?

A: The regulatory documents describe different durations depending on the form and area of application. Dermal (skin) and scalp treatments are typically authorized for a short-term duration of up to four weeks. The topical solution used for nail application is authorized for a potentially extended duration of therapy.

Q: Are there different forms (like cream, gel, solution) of Piroctol?

A: Piroctol is available in multiple topical forms designed for different applications. These formulations include cream, lotion, medicated shampoo, topical solution (lacquer), and gel.

Q: Can Piroctol affect my kidneys or liver?

A: Official regulatory assessments indicate very low systemic bioavailability (less than 2% absorption) following topical application. This minimal absorption is the reason systemic organ-specific warnings related to kidney or liver function are not typically featured in the drug's official labeling for topical use.

Q: Does Piroctol make skin more sensitive to sunlight?

A: Official studies, including phototoxicity and Photo-Draize studies, have been conducted on the active substance. These studies indicated no phototoxicity or photo-contact sensitization due to the active substance in Piroctol.

Q: How do I know if I'm using Piroctol correctly?

A: Official documents outline specific procedural requirements for each form to ensure proper use. This includes specific timeframes for contact, application frequency, and periodic removal requirements for different formulations.

Q: Is Piroctol the same type of medicine as [similar drug name]?

A: Official classifications describe Piroctol as a hydroxypyridone antifungal agent. Its mechanism of action is structurally distinct from other common antifungal classes, such as the azole or allylamine groups, which is recognized as an alternative treatment approach in official literature.

Q: Is it normal to feel [mild, common sensation] after using Piroctol?

A: Official regulatory documents indicate that common side effects can include mild burning, itching, or redness at the site of application. Individuals using the medicine may observe mild common sensations. It is important to know the signs of increased irritation or severe reactions like blistering or swelling.

Q: Does Piroctol cause sleepiness or drowsiness?

A: Regulatory documents list potential adverse reactions but do not commonly cite sleepiness or drowsiness as an adverse reaction associated with the topical use of Piroctol.

Q: Are there any foods or drinks I should avoid while using Piroctol?

A: Official regulatory assessments cite no documented systemic pharmacokinetic interactions with food or drinks. This is consistent with the drug’s very low systemic absorption into the body.

Q: What should I look for if I suspect a serious side effect from Piroctol?

A: Official documents advise watching for signs of severe local irritation, such as blistering, swelling, or oozing at the application site. Signs of a serious allergic reaction, such as hives, swelling of the face, or difficulty breathing, are also listed in official information as being conditions that warrant prompt professional assistance.

Q: Can Piroctol be used by pregnant women?

A: Piroctol has been assigned to a category (Category B) indicating that animal studies have not demonstrated fetal harm, but there are no adequate and well-controlled studies in pregnant women. Use during pregnancy is conditional and requires a medical assessment of potential benefit versus risk.

Q: Is it okay to use Piroctol if I am breastfeeding?

A: Regulatory documents advise caution when administering Piroctol to nursing mothers. It is noted that, due to minimal absorption into the body, little excretion into human milk is expected.

Q: What is the shelf life of Piroctol?

A: The official regulatory requirement is that the product be stored according to labeling instructions at 20 C to 25 C. The official shelf life and expiration date are printed directly on the product's packaging and container.

Q: Is Piroctol absorbed into the bloodstream?

A: The active substance in Piroctol is absorbed into the bloodstream in a very small amount. Official pharmacokinetic studies show that on average, less than 2% of the dose applied topically is absorbed systemically, and it is described as being rapidly excreted from the body.

Q: What specific components of Piroctol are known allergens?

A: Official regulatory information describes the use of Piroctol as being contraindicated for individuals with known hypersensitivity to the active ingredient or any components in the formulation. Official product descriptions list specific inactive ingredients (excipients) in the base, such as benzyl alcohol and cetyl alcohol, to which an individual may have a known allergy.

Q: What is the chance of getting a serious side effect from Piroctol?

A: Official regulatory documents list the inherent potential for severe adverse reactions, such as skin corrosion and serious eye damage. However, regulatory bodies often do not formally categorize the frequency of these reactions using standard clinical trial frequency bands.

Q: Are there any specific lifestyle restrictions mentioned for Piroctol use?

A: The main lifestyle restriction in official documents is that washing, bathing, or swimming must be avoided for at least 8 hours following the application of the nail lacquer formulation. No similar restrictions are explicitly noted for other forms.

Q: Where can I find the official patient information leaflet for Piroctol?

A: Official regulatory labeling, such as the full Prescribing Information or the Patient Information Leaflet, can be located through governmental drug information databases, such as those provided by the FDA or the NIH DailyMed.

Q: Can Piroctol be used alongside pain relievers?

A: Regulatory assessments cite no documented systemic pharmacokinetic interactions with other medicinal products, including common pain relievers. This finding is consistent with the drug’s minimal systemic absorption.

Q: Does Piroctol have any effect on blood pressure?

A: Due to minimal systemic absorption (less than 2%) following topical application, Piroctol is not expected to have an effect on blood pressure. Systemic safety reviews in animal models also showed no effect on coagulation or other major physiological markers.

Q: Is Piroctol approved in [major country/region]?

A: Piroctol is an approved medicine and is authorized for use by regulatory bodies in major regions, including the United States (US), Canada (CA), and Australia (AU).

Q: Do I need a prescription to get Piroctol?

A: The majority of Piroctol formulations are designated as 'Prescription Only' (Rx Only) by major regulatory authorities in the United States and Canada. Some countries or lower-concentration formulations may be classified as Pharmacy Medicine.

Q: Is Piroctol a controlled substance?

A: Official regulatory documents in the United States list the drug's DEA Schedule as None, meaning it is not classified as a controlled substance.

Q: How is Piroctol packaged and dispensed?

A: Piroctol is packaged and dispensed as a topical formulation (such as cream, solution, or shampoo). Official instructions state the container must be stored tightly closed in its original packaging to maintain product stability.

How should Piroctol be stored and disposed of?

Piroctol (Ciclopirox Olamine) must be stored strictly according to the conditions defined in the official regulatory labeling.

Storage Requirements

The required storage temperature is 20 C to 25 C (68 F to 77 F), which aligns with Controlled Room Temperature. The medication must not be frozen, as this can compromise product stability. It is mandatory to keep the product out of the sight and reach of children and store the container tightly closed in its original packaging.

Disposal Instructions

Unused or expired Piroctol must be disposed of according to local regulatory requirements for pharmaceutical waste. Disposal should be handled via an approved drug take-back program. If a take-back program is unavailable, the product should be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed for disposal in household trash; it must not be put into wastewater (e.g., flushed down the toilet).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Piroctol found in:

A-Z Index: